Chronic gonadal toxicity in patients with testicular cancer after chemotherapy

Kreuser, E. D.; Harsch, U.; Hetzel, W. D.; Schreml, W.

doi:10.1016/0277-5379(86)90393-7

Cited by 67 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This stem cell killing effect may be responsible for the delay of more than 3 months in recovery of normospermic counts observed in this group. Similar patterns of delayed recovery of sperm production were observed with regimens containing cisplatin (PVB),24 cisplatin plus Adriamycin (PVB + ADR), 22,23 and Adriamycin plus dacarbazine (ABVD).2s…”

Section: Discussionmentioning

confidence: 61%

Recovery of sperm production after chemotherapy for osteosarcoma

Meistrich

Chawla

Cunha

et al. 1989

Cancer

120

View full text Add to dashboard Cite

Because treatment with surgery and combination chemotherapy produces a high cure rate in young men with osteosarcoma, their subsequent reproductive function is an important concern. Semen analyses of osteosarcoma patients, therefore, were performed before, during, and after treatment with the PADIC regimen consisting of cisplatin, Adriamycin (doxorubicin), and dacarbazine or, in some cases, the PADIC regimen plus additional drugs. Results showed that semen volume was not affected and that sperm motility was reduced only during treatment. Although nearly all patients were rendered azoospermic during treatment, sperm production resumed in 30 of 32 patients examined at least 2 years after treatment. Analysis with correction for censored data indicates that, in 78% of treated men, sperm counts will return to more than 10 million/ml. The percentage of men whose sperm counts recovered to normal was lower for those receiving cisplatin dosages greater than or equal to 600 mg/m2; no trends were observed with Adriamycin and dacarbazine dosages. The inclusion of additional drugs such as methotrexate, bleomycin, dactinomycin, or cyclophosphamide (less than 4 g/m2) did not significantly affect the recovery of spermatogenesis. We conclude that the risk of long-term infertility from treatment with the PADIC regimen is low.

show abstract

Section: Discussionmentioning

confidence: 61%

Recovery of sperm production after chemotherapy for osteosarcoma

Meistrich

Chawla

Cunha

et al. 1989

Cancer

120

View full text Add to dashboard Cite

show abstract

“…We have shown one of the determinants of the numbers of motile, normal and live sperm and of qualitative sperm motility is the extent of chemotherapy received with patients having higher cumulative doses or a greater number of courses having more abnormal values. It is also clear from this and other studies that, if the final impact of chemotherapy on fertility is to be determined, patients must be followed up for at least three years and probably longer (Kreuser et al, 1986). It has previously been reported that, following hemicastration for testicular cancer, many patients have raised LH and FSH levels (Fossa et al, 1980).…”

Section: Thyroidfunctionmentioning

confidence: 87%

Long-term toxicity of chemotherapy for testicular cancer – the cost of cure

Stuart

Woodroffe²,

Grundy³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidectomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin. TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were normal in all. FSH was raised in 67% of the chemotherapy group and in 45% of the orchidectomy group while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. MethodsClinical notes were reviewed to obtain details of investigations at presentation and of chemotherapy received. Hepatic and renal function, serum TSH, free thyroxine and free T3, serum FSH, LH and testosterone, tumour markers (afetoprotein and P-human chorionic gonadotrophin) and full blood count were measured. Standard laboratory normal ranges were used and serum hormones were measured by specific immunometric methods.Pulmonary function assessment comprised measurement of vital capacity (VC), forced residual capacity (FRC), residual volume (RV), total lung capacity (TLC), forced expiratory capacity in one second (FEV,), peak expiratory flow rate (PFR), transfer factor coefficient (KCO), total lung transfer factor (TLCO), total alveolar volume (TAV) and effective alveolar volume (EAV). TLCO was measured by single breath-hold method with correction for haemoglobin concentration, EAV by single breath helium dilution and lung volumes by steady state helium dilution. Values other than TAV and EAV were expressed as standardised residuals (Miller & Pincock, 1988) with expected values determined from height and age by published regression equations (European Coal and Steel Community Recommendations, 1983

show abstract

“…Recovery of spermatogenesis, if any, should occur within a few years after chemotherapy. [15][16][17][18] Persistent azoospermia years after chemotoxic exposure, like in our series of patients who had been azoospermic for an average duration of 16 years, carries a dismal prognosis for spermatogenic recovery. Prior to the era of TESE-ICSI, which allows direct injection of individual sperm into the oocyte, leading to fertilization and pregnancy, these men were considered sterile and donor-sperm insemination or adoption were the only available options for these men to have children.…”

Section: Discussionmentioning

confidence: 99%

Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy

Chan

Palermo

Veeck

et al. 2001

Cancer

129

View full text Add to dashboard Cite

Schizophrenia or schizoaffective disorders are often found in patients affected by DiGeorge/velo‐cardio‐facial syndrome (DGS/VCFS) as a result of hemizygosity of chromosome 22q11.2. We evaluated the UFD1L gene, mapping within the DGS/VCFS region, as a potential candidate for schizophrenia susceptibility. UFD1L encodes for the ubiquitin fusion degradation 1 protein, which is expressed in the medial telencephalon during mouse development. Using case control, simplex families (trios), and functional studies, we provided evidence for association between schizophrenia and a single nucleotide functional polymorphism, −277A/G, located within the noncoding region upstream the first exon of the UFD1L gene. The results are supportive of UFD1L involvement in the neurodevelopmental origin of schizophrenia and contribute in delineating etiological and pathogenetic mechanism of the schizophrenia subtype related to 22q11.2 deletion syndrome. © 2001 Wiley‐Liss, Inc.

show abstract

Chronic gonadal toxicity in patients with testicular cancer after chemotherapy

Cited by 67 publications

References 12 publications

Recovery of sperm production after chemotherapy for osteosarcoma

Recovery of sperm production after chemotherapy for osteosarcoma

Long-term toxicity of chemotherapy for testicular cancer – the cost of cure

Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy

Contact Info

Product

Resources

About